Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

• Main Authors: Kazuhiro Kamata, Kazuaki Jindai, Nao Ichihara, Hiroki Saito, Hideaki Kato, Hiroyuki Kunishima, Ayumi Shintani, Osamu Nishida, Shigeki Fujitani
• Format: Article
• Language: English
• Published: BMC 2021-04-01
• Series: Journal of Intensive Care
• Subjects: Randomized controlled trial; REMAP-CAP (Randomized; Embedded; Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia); COVID-19; Emerging infectious disease
• Online Access: https://doi.org/10.1186/s40560-021-00547-7

Abstract REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.